BBIO: Oppenheimer Initiates
Oppenheimer assumes BridgeBio Oncology at Outperform with a price target of $22
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Oppenheimer assumes BridgeBio Oncology at Outperform with a price target of $22
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.